West Pharmaceutical Services (STU:WPS) Beneish M-Score: -2.48 (As of Jun. 26, 2026)


STU:WPS West Pharmaceutical Services Inc STU:WPS
87 GF Score
Price €305.30
GF Value €318.57
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is West Pharmaceutical Services Beneish M-Score?

West Pharmaceutical Services STU:WPS +1.43% 87 Beneish M-Score is -2.48 as of Jun. 26, 2026. GuruFocus rates STU:WPS with a GF Score™ of 87/100 and a GF Value™ of €318.57 (Fairly Valued). The stock has 9 warning signs investors should review. Among 766 Medical Devices & Instruments companies, West Pharmaceutical Services ranks worse than 59.66% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.48 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for West Pharmaceutical Services's Beneish M-Score or its related term are showing as below:

STU:WPS' s Beneish M-Score Range Over the Past 10 Years
Min: -2.85   Med: -2.54   Max: -2.14
Current: -2.48

During the past 13 years, the highest Beneish M-Score of West Pharmaceutical Services was -2.14. The lowest was -2.85. And the median was -2.54.


West Pharmaceutical Services Beneish M-Score Historical Data

* Premium members only.

The historical data trend for West Pharmaceutical Services's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

West Pharmaceutical Services Beneish M-Score Chart

West Pharmaceutical Services Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.17 -2.45 -2.71 -2.48 -2.74

West Pharmaceutical Services Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.54 -2.46 -2.56 -2.74 -2.48

STU:WPS vs RMD, MDLN, SOLV: Beneish M-Score Comparison

For the Medical Instruments & Supplies subindustry, West Pharmaceutical Services's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


West Pharmaceutical Services Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, West Pharmaceutical Services's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where West Pharmaceutical Services's Beneish M-Score falls into.


STU:WPS
87GF Score
West Pharmaceutical Services Inc STU:WPS
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

West Pharmaceutical Services Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of West Pharmaceutical Services for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1443+0.528 * 0.9525+0.404 * 0.9735+0.892 * 1.0307+0.115 * 0.9579
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0715+4.679 * -0.032864-0.327 * 1.0555
=-2.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was €593 Mil.
Revenue was 730.838 + 687.47 + 685.519 + 664.555 = €2,768 Mil.
Gross Profit was 256.386 + 259.531 + 250.744 + 237.471 = €1,004 Mil.
Total Current Assets was €1,580 Mil.
Total Assets was €3,555 Mil.
Property, Plant and Equipment(Net PPE) was €1,568 Mil.
Depreciation, Depletion and Amortization(DDA) was €152 Mil.
Selling, General, & Admin. Expense(SGA) was €348 Mil.
Total Current Liabilities was €583 Mil.
Long-Term Debt & Capital Lease Obligation was €255 Mil.
Net Income was 120.062 + 112.813 + 119.28 + 114.271 = €466 Mil.
Non Operating Income was -3.633 + -16.141 + -6.049 + -4.682 = €-31 Mil.
Cash Flow from Operations was 77.763 + 214.439 + 168.014 + 153.546 = €614 Mil.
Total Receivables was €503 Mil.
Revenue was 645.65 + 715.104 + 672.957 + 652.251 = €2,686 Mil.
Gross Profit was 214.507 + 261.288 + 238.495 + 213.67 = €928 Mil.
Total Current Assets was €1,348 Mil.
Total Assets was €3,347 Mil.
Property, Plant and Equipment(Net PPE) was €1,605 Mil.
Depreciation, Depletion and Amortization(DDA) was €148 Mil.
Selling, General, & Admin. Expense(SGA) was €315 Mil.
Total Current Liabilities was €487 Mil.
Long-Term Debt & Capital Lease Obligation was €260 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(593.044 / 2768.382) / (502.83 / 2685.962)
=0.21422 / 0.187207
=1.1443

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(927.96 / 2685.962) / (1004.132 / 2768.382)
=0.345485 / 0.362714
=0.9525

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1580.182 + 1567.726) / 3554.977) / (1 - (1348.187 + 1604.967) / 3346.835)
=0.114507 / 0.117628
=0.9735

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2768.382 / 2685.962
=1.0307

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(148.227 / (148.227 + 1604.967)) / (151.766 / (151.766 + 1567.726))
=0.084547 / 0.088262
=0.9579

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(348.09 / 2768.382) / (315.203 / 2685.962)
=0.125738 / 0.117352
=1.0715

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((255.002 + 583.01) / 3554.977) / ((260.295 + 487.197) / 3346.835)
=0.235729 / 0.223343
=1.0555

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(466.426 - -30.505 - 613.762) / 3554.977
=-0.032864

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

West Pharmaceutical Services has a M-score of -2.54 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.48 mean?
West Pharmaceutical Services (STU:WPS) has a Beneish M-Score of -2.48 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on West Pharmaceutical Services and its competitors. According to the industry distribution chart, West Pharmaceutical Services ranks #457 out of 766 companies in the Medical Devices & Instruments industry, placing it in the top 59.7%.
Is West Pharmaceutical Services' Beneish M-Score too high?
West Pharmaceutical Services' current Beneish M-Score is -2.48. Based on the distribution chart, West Pharmaceutical Services ranks #457 out of 766 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, West Pharmaceutical Services has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does West Pharmaceutical Services' Beneish M-Score compare to RMD and MDLN?
According to the Medical Devices & Instruments industry distribution chart, West Pharmaceutical Services ranks #457 out of 766 companies for Beneish M-Score. This places West Pharmaceutical Services in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on West Pharmaceutical Services and its competitors. West Pharmaceutical Services's current Beneish M-Score is -2.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is West Pharmaceutical Services stock overvalued right now?
Based on GuruFocus' analysis, West Pharmaceutical Services (STU:WPS) is currently considered Fairly Valued. The stock's GF Value™ is €318.57, compared to a current price of €305.30 — trading 4.2% below its estimated fair value. The current Beneish M-Score is -2.48. West Pharmaceutical Services' overall GF Score™ is 87/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For West Pharmaceutical Services (STU:WPS), the current Beneish M-Score is -2.48 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is West Pharmaceutical Services (STU:WPS) Overvalued in 2026?

Based on GuruFocus' analysis, West Pharmaceutical Services stock appears to be undervalued. The current stock price of €305.30 is trading 4.2% below its estimated GF Value™ of €318.57. GuruFocus considers West Pharmaceutical Services to be Fairly Valued.

Key valuation signals for STU:WPS:

  • Beneish M-Score: -2.48
  • GF Value™: €318.57 vs. price of €305.30 (4.2% below fair value)
  • GF Score™: 87/100 with 9 warning signs

No single metric tells the full story. See the STU:WPS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


West Pharmaceutical Services Business Description

Address 530 Herman O. West Drive, Exton, PA, USA, 19341-1147
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
87GF Score

Get the complete analysis for STU:WPS

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€305.30
Price
€318.57
GF Value